The New Patient Pipeline

McKinsey report

The surge in GLP-1 medications like semaglutide and tirzepatide is not only revolutionizing weight management but also reshaping the medical aesthetics industry.

 

A recent McKinsey study has revealed that 63% of patients pursuing aesthetic treatments after starting GLP-1s had never received any aesthetics procedure before.

McKinsey report

 

These patients are entering the market with fresh concerns – skin laxity, volume loss and facial changes – driven by rapid weight loss. They’re looking fro trusted providers to guide them.

Now you can be their GLP-1 provider – and their aesthetic provider! When you guide patients through weight loss, you naturally become their trusted source for what comes next – including aesthetic care.

DrWell gives you all of the tools to seamlessly manage a weight and wellness program with:

  • Streamlined medication management
  • Simple patient registration
  • Automated program billing
  • Simple, personalized virtual care\

Start growing you practice with us. Book a demo today to learn more.